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Generation and biochemical analysis of human effector CD4 T cells: alterations
in tyrosine phosphorylation and loss of CD3zexpression
Sandeep Krishnan, Vishal G. Warke, Madhusoodana P. Nambiar, Henry K. Wong, George C. Tsokos, and Donna L. Farber
Human effector T cells have been difﬁcult
to isolate and characterize due to their
phenotypic and functional similarity to
the memory subset. In this study, a bio-
chemical approach was used to analyze
human effector CD4 T cells generated in
vitro by activation with anti-CD3 and au-
tologous monocytes for 3 to 5 days. The
resultant effector cells expressed the ap-
propriate activation/differentiation mark-
ers and secreted high levels of interferon
g (IFN-g) when restimulated. Biochemi-
cally, effector CD4 T cells exhibited in-
creases in total intracellular tyrosine
phosphorylation and effector-associated
phosphorylated species. Paradoxically,
thesealterationsintyrosinephosphoryla-
tion were concomitant with greatly re-
duced expression of CD3z and CD3e sig-
naling subunits coincident with a
reduction in surface T-cell receptor (TCR)
expression. Because loss of CD3z has
also been detected in T cells isolated ex
vivofromindividualswithcancer,chronic
viralinfection,andautoimmunediseases,
the requirements and kinetics of CD3z
down-regulationwereexamined.Theloss
of CD3z expression persisted throughout
the course of effector T-cell differentia-
tion, was reversible on removal from the
activating stimulus, and was modulated
byactivationconditions.Thesebiochemi-
cal changes occurred in effector T cells
generated from naive or memory CD4
T-cellprecursorsanddistinguishedeffec-
tor from memory T cells. The results
suggest that human effector T-cell differ-
entiation is accompanied by alterations in
the TCR signal transduction and that loss
of CD3z expression may be a feature of
chronic T-cell activation and effector gen-
erationinvivo.(Blood.2001;97:3851-3859)
© 2001 by TheAmerican Society of Hematology
Introduction
The initiation of adaptive immune responses depends on the
activation and differentiation of naive T cells into effector cells that
migrate to antigenic sites to orchestrate immune-mediated antigen
clearance. Effector T cells can also predominate in diseases
characterized by chronic immune activation, such as the autoim-
mune diseases systemic lupus erythematosus (SLE)1 and rheuma-
toid arthritis,2 and chronic viral infections,3 and during acute
rejection of transplanted tissue.4 Thus, characterization of the
effector T-cell subset at the mechanistic level is essential to
understand its role in normal and pathologic immune states.
Effector T-cell differentiation involves a series of profound
cellular and molecular changes, including an increase in size,
up-regulation of activation/differentiation markers such as CD69,
CD25, and CD45RO,5 transcription of effector cytokine genes such
as interferon g (IFN-g) and interleukin-4 (IL-4),6 and reconﬁguring
of chromatin structure in the regions of these differentially
expressed genes.7 In contrast to naive CD4 T-cell precursors, the
resultant effector CD4 T cells produce high levels of effector
cytokines, can be reactivated in the absence of costimulation,8,9 and
exhibit an increased susceptibility to apoptosis.8
The disparate functions and activation requirements of effector
and naive CD4 T cells suggest that distinct signals are being
transduced through the T-cell receptor (TCR) in these subsets;
however TCR-mediated signaling in effector CD4 T cells is not
well characterized. Studies on TCR-mediated signaling pathways
have largely focused on proximal signaling events in T-cell lines
and differentiated T-cell clones that occur minutes after TCR
triggering.10 These studies have revealed that phosphorylation of
the TCR-associated CD3z subunit by the T-cell–speciﬁc p56lck
kinase and subsequent recruitment and activation of the CD3z-
associated kinase ZAP-70, are critical proximal events in T-cell
activation.11,12 Although CD3z and other proximal phosphoryla-
tion events occur minutes after TCR ligation, effector T-cell
differentiation occurs over a period of 3 to 5 days of activation,6
and the biochemical events underlying this differentiation process
are not known.
Effector T-cell differentiation is not viewed as a terminal event.
Although most effector T cells are believed to die after a brief life
span, a small proportion is believed to revert to the resting state to
become long-lived resting memory T cells.13 This lineage relation-
ship has been difﬁcult to establish due to the phenotypic and
functional similarities between effector and memory CD4 T cells.14
We have recently found that mouse effector and memory CD4 T
cells can be distinguished based on tyrosine phosphorylation of
intracellular substrates,15 suggesting that biochemical analysis ofT-
cell subsets may be reliable criteria by which to assess their
differentiation state.
Although the majority of effector T-cell analyses have been
carried out in the mouse, studies with human effector T cells have
lagged behind for 2 main reasons. First, human effector T cells are
difﬁcult to identify due to their phenotypic and functional similar-
ity to memory T cells14; second, there is no human corollary to the
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large numbers of antigen-speciﬁc human effector T cells. Given
these limitations, it is necessary to develop in vitro systems for the
generation and characterization of human effector T cells.
In this study, we have generated large numbers of differentiated
human effector T cells in vitro from highly puriﬁed resting CD4 T
cells for subsequent biochemical analysis. The resultant in vitro–
activated T cells exhibit the phenotypic and functional properties
associated with differentiated effector CD4 T cells. Biochemically,
effector CD4 T cells can be distinguished from resting CD4 T cell
precursors by quantitative and qualitative differences in total
tyrosine phosphorylation and a profound loss of CD3z and CD3e
protein expression, whereas expression of the CD3z-associated
kinase ZAP-70 remains unchanged. This loss of CD3 expression
coincided with loss of surface TCR expression, persisted during
effectorT-cell differentiation, and was reversible once effector cells
were removed from the activating stimulus. Our ﬁndings strongly
suggest that speciﬁc changes in the TCR signaling apparatus
characterize effector CD4 T-cell differentiation and that loss of
CD3z may be a feature of chronic T-cell activation.
Materials and methods
Human cells
Heparinized peripheral venous blood was obtained from healthy adult
volunteers. Written informed consent was obtained from all participating
subjects and the protocol of study was approved by the Health Use
Committee of the Walter Reed Army Medical Center. Peripheral blood
mononuclear cells (PBMCs) were puriﬁed through Ficoll Hypaque and
monocytes obtained by elutriation were 90% CD141.
Antibodies
The following antihuman antibodies were purchased from Pharmingen (San
Diego, CA): anti-CD3 (clone UCHT1), phycoerythrin (PE)–conjugated
anti-abTCR (clone T10B9.1A-31), ﬂuorescein isothiocyanate (FITC)–
conjugated anti-CD25 (clone M-A251), FITC-conjugated anti-CD14 (clone
M5E2), FITC-conjugated anti-CD45RA (clone HI100), PE-conjugated
anti-CD45RO (clone UCHL1), FITC-conjugated anti-CD69 (clone FN50),
and anti-CD28 (clone CD28.2). PE-conjugated anti-CD4 (clone Q4120)
and FITC-conjugated anti-CD3 were purchased from Sigma (St Louis,
MO). The monoclonal antiphosphotyrosine antibody (clone 4G10) was
purchased from Upstate Biotechnology (Lake Placid, NY). The anti-CD3z
antiserum was described previously.16 Anti–ZAP-70 antiserum16 was
previously described.Anti-CD3 antibody (clone OKT3) was obtained from
Ortho Biotech (Raritan, NJ) and immunoglobulin M (IgM) anti-CD3 (clone
2Ad2A2) was generously provided by Dr Ellis Reinherz (Dana-Farber
Cancer Institute, Boston, MA).
Isolation of naive and memory CD4 T-cell subsets
CD4 T cells were obtained from PBMCs using a CD4 T-cell isolation kit
(Miltenyi Biotec, Auburn, CA) according to the manufacturer’s instruc-
tions. The resultant CD4 T cells were more than 95% pure as determined by
ﬂuorescence-activated cell sorter (FACS) analysis. Further fractionation
into CD45RA and CD45RO subsets was achieved using anti-CD45RO– or
anti-CD45RA–conjugated microbeads (Miltenyi Biotec) to deplete the
CD45RO1 and CD45RA1 subsets, respectively. The resulting purity of
CD45RA and CD45RO subsets was between 93% and 96%. For antigen-
presenting cells (APC), puriﬁed monocytes were treated with 100 mg/mL
mitomycin C (Boehringer Mannheim, Indianapolis, IN) for 1 hour at 4°C
and washed 4 times with RPMI medium before culture.
In vitro generation of effector CD4 T cells
Primary effector CD4 T cells were generated in 24-well plates by
incubating 106 CD45RA or whole CD4 T cells with 2 mg/mL anti-CD3
(OKT3 or UCHT1) antibody in soluble form plus 2 3 106 autologous,
mitomycin C-treated monocytes for 72 hours at 37°C in complete RPMI
media, consisting of RPMI 1640 (Gibco/BRL, Grand Island, NY), 10%
fetal calf serum (Gemini Bioproducts, Calabasas, CA), 50 U/mL penicillin/
streptomycin(Gibco),2mMglutamine(Gibco),and50mMb-mercaptoetha-
nol (Sigma). The concentration of anti-CD3 antibody used was similar to
another study17 and was titrated to be the lowest dose for effector T-cell
differentiation as assessed by phenotype (data not shown). Effectors were
puriﬁed through Ficoll (LSM, ICN/Cappel, San Diego, CA) and washed
twice in RPMI, resulting in 95% purity. Residual monocytes were further
depleted from effector T-cell preparations using anti-CD14–coupled Dyna-
beads (Dynal, Lake Success, NY) following the manufacturer’s recommen-
dations resulting in 99% purity by FACS analysis.
Cytokine assays
For analysis of IFN-g production, 105 naive, effector or memory CD4 T
cells were cultured on 2 mg/mL anti-CD3 (OKT3) immobilized on plastic.
After 24 hours, supernatants were collected, and IFN-g content was
quantitated by speciﬁc enzyme-linked immunosorbent assay (ELISA) using
matched antibody pairs (Endogen, Cambridge, MA).
Western blotting
Cells (2 3 106 cells in 100mL RPMI) were left untreated or activated for 2
minutes at 37°C with IgM anti-CD3 antibody and immediately lysed in cold
1% NP40 lysis buffer with protease/phosphatase inhibitors.16 Lysates were
analyzed by 12% to 12.5% sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE), gels were transferred to nitrocellulose and
blots hybridized to antiphosphotyrosine or to anti-CD3z or anti–ZAP-70
antiserum followed by horseradish peroxidase (HRP)–conjugated goat
antimouse (Bio-Rad, Hercules, CA) or protein A–peroxidase (Sigma) as
described.16 Bands were detected using enhanced chemiluminescence
(ECL, Amersham, Arlington Heights, IL) and revealed with Hyperﬁlm
ECL(Amersham).
Flow cytometry
For analysis of cell surface phenotype, cells were washed, resuspended in
stain buffer (phosphate-buffered saline [PBS]11% fetal calf serum [FCS]1
0.05% sodium azide) containing directly conjugated antibodies for 30
minutes at 4°C. Stained cells were analyzed using the FACScalibur (Becton
Dickinson, San Jose, CA) with Cellquest software.
Reverse transcriptase–polymerase chain reaction
Total RNAwas isolated by using a RNeasy minikit (Qiagen, Valencia, CA)
from 5 3 106 whole CD4 and effector CD4 T lymphocytes. Using 400 ng
total RNA, complementary DNA (cDNA) was synthesized with AMV
reverse transcriptase (RT) (Promega, Madison, WI) and polymerase chain
reaction (PCR)–ampliﬁed using CD3z chain and b-actin speciﬁc primers.
Primers for PCR were synthesized by Sigma-Genosys (The Woodlands,
TX): CD3z chain: 59-AGCCTCTGCCTCCCAGCCTCTTTCTGAG-39,
(nucleotides 34-6218) and 59-TCAGTGGCTGAGAAGAGTGAACC-
GGGTTG-39 (nucleotides 669-64118), ZAP-70: 59-GACGTGGCCA-
TCAAGGTGCTGAAGCAG-39 and 59-GCGCTGCTCCACGGTCAG-
GAAGTCG-39, and b-actin: 59-CATGGGTCAGAAGGATTCCT-39 and
59-AGCTGGTAGCTCTTCTCCA-39. PCR products were electrophoresed
on 1.2% SeaKem agarose gel (FMC Bioproducts, Rockland, ME) and
visualized with ethidium bromide.
Results
In vitro generation of effector CD4 T cells
For generation of primary effector CD4 T cells, we isolated highly
puriﬁed, resting naive (CD45RA) CD4 T cells from human
peripheral blood using a 2-step immunodepletion procedure and
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presence of puriﬁed autologous peripheral blood monocytes as
APC. Monocytes express the costimulatory ligands B7-1/B7-219
and Fcg receptors for cross-linking anti-CD3 on the T-cell surface.
To establish that differentiated effector CD4 T cells were generated
using these stimulation conditions (anti-CD3/monocytes), we as-
sessed the ability of the resultant cell population to produce the
effector cytokine IFN-g compared to primary naive (CD45RA) and
memory (CD45RO) CD4 T-cell subsets puriﬁed from peripheral
blood. Consistent with previous studies,20 resting naive CD4Tcells
produced no IFN-g in the resting state and negligible levels when
activated with immobilized anti-CD3 (Figure 1A). By contrast, in
vitro–generated effector CD4 T cells and ex vivo memory CD4 T
cells produced high levels of IFN-g when restimulated with
anti-CD3 (Figure 1A), although the level of IFN-g produced by
effectorTcells was consistently higher than memory cells—similar
to mouse effector CD4 T cells generated with anti-CD3/APC or
antigen/APC and ex vivo mouse memory CD4 T cells.15,21 These
data indicate that human effector T cells generated here are
functionally differentiated.
We also analyzed the expression of surface activation and
differentiation markers to ensure that activation of naive CD4 T
cells with anti-CD3/monocytes resulted in differentiation to effec-
tor cells. We found that the activation markers CD25 and CD69
were up-regulated 24 to 48 hours after activation (Figure 1B, rows
3 and 4), whereas up-regulation of the effector/memory differentia-
tion marker CD45RO occurred at later times (between 48 and 72
hours, row 2, Figure 1B). CD69 and CD25 were down-regulated by
72 hours, similar to their down-regulation on mouse effector CD8T
cells,22 whereas CD45RO remained up-regulated during prolonged
culture for 120 hours and later (Figure 1B and data not shown). No
up-regulation of activation/differentiation markers was observed in
the control culture containing naive CD4 T cells incubated with
monocytes alone for 72 hours (Figure 1B, last column). Effector T
cells are also distinguished from resting counterparts based on large
size,22 and as shown in the bottom row of Figure 1B, cell size
increased with activation time and the effector cells exhibited a
uniform large size after 72 hours activation. When taken together,
the functional and phenotypic results presented in Figure 1 indicate
that these in vitro activation conditions result in the generation of
differentiated effector CD4 T cells.
Tyrosine phosphorylation and CD3z expression
in effector CD4 T cells
To undertake a biochemical analysis of in vitro–generated effector
CD4 T cells, it was ﬁrst necessary to rigorously establish the purity
of the resultant effector T-cell population. Initial puriﬁcation of
effector CD4 T cells by Ficoll centrifugation resulted in approxi-
mately 5% residual monocyte contamination as assessed by CD14
staining (Figure 2A, left-most plot). We removed these residual
monocytes with anti-CD14–conjugated magnetic beads, resulting
in less than 1.5% monocyte contamination (Figure 2A, right-hand
plot). This puriﬁed effector population consisted almost exclu-
sively of CD4 T cells (Figure 2B).
We evaluated the TCR-coupled signaling proﬁle of puriﬁed
effector T cells relative to resting CD4 T-cell precursors, by
analyzing the pattern of total tyrosine phosphorylation before and
after TCR/CD3 cross-linking by antiphosphotyrosine immunoblot-
ting of whole cell lysates (Figure 3A). We found that the pattern of
tyrosine phosphorylation in resting and effector CD4 T cells
differed both quantitatively and qualitatively. Quantitatively, un-
stimulated effector CD4 T cells exhibited a higher level of
phosphorylation overall and a greater number of phosphorylated
species compared to unstimulated CD4 T cells apparent when cell
or protein equivalents were compared (Figure 3A, compare lanes 3
and 5 to lane 1). Following CD3 cross-linking, the extensive
phosphorylationineffectorcellspersisted,withincreasedphosphor-
ylation of 37- to 41-kd and 70- to 80-kd proteins (Figure 3A, lanes
Figure 1. In vitro–generated effector CD4 T cells exhibit effector function and
an activated/effector phenotype. Naive (CD45RA) and memory (CD45RO) sub-
sets of CD4 T cells were puriﬁed by a 2-step immunomagnetic depletion (see
“Materials and methods”). Effector CD4 T cells were generated by coculture of naive
CD4 T cells with 2 mg/mLanti-CD3 antibody (OKT3) and twice the number of primary
autologous monocytes for 3 days. (A) Functional analysis of naive, effector, and
memory CD4 T cells. Freshly isolated ex vivo naive and memory CD4 T cells and in
vitro–generated effector CD4 T cells puriﬁed by centrifugation through Ficoll and
washing, were cultured alone or in wells to which anti-CD3 antibody was immobilized.
After 24 hours, culture supernatants were collected and assayed for IFN-g content by
speciﬁc ELISA. These data are representative of 3 separate experiments. (B)
PhenotypicanalysisofeffectorCD4T-celldifferentiation.Theexpressionofactivation/
differentiation markers on puriﬁed naive (CD45RA) CD4 T cells, naive cells activated
for 24 to 72 hours with anti-CD3 and autologous monocytes to generate effectors,
and naive cells incubated for 72 hours with monocytes alone as a control was
assessed by speciﬁc staining with ﬂuorescent-conjugated antibodies and analyzed
by FACS. Forward scatter is shown at the bottom. These data from a single donor are
representative of 3 separate experiments using T cells derived from 3 differ-
ent donors.
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phosphorylated protein species of 36 kd, 55 kd, 70 to 80 kd, and
120 to 130 kd (Figure 3A, lane 2). Qualitative differences in
tyrosine phosphorylation were also apparent in effector versus
resting CD4 T cells and included phosphorylated proteins found
only in effector cells or present to a much greater level in effector
cells. These effector-associated phosphorylated species (indicated
by arrows to the right of the blot in Figure 3A) of molecular
weights 120, 60 to 80 kd (p60, p72, p76), 36 to 40 kd (p37 and
p40/41), and 10 kd (p10, lanes 3 and 4) were consistently present in
effector T cells generated from T cells of 20 different donors and
are similar in size to phosphorylated proteins we previously
detected in mouse effector CD4 T cells.15 Despite these phosphory-
lation increases in effector cells, there was a notable absence of 2
phosphoproteins present in resting or CD3–cross-linked CD4 T
cells—one protein of approximately 18 kd corresponding in size to
phosphorylated CD3z (Figure 3A, lanes 1 and 2) and a second
135-kd protein.
The apparent lack of phosphorylated CD3z in effector T cells
was paradoxical given that CD3z phosphorylation is a critical event
to induce downstream phosphorylation cascades.23 We thus ex-
plored CD3z protein expression in effector cells by reprobing the
phosphotyrosine immunoblot in Figure 3A with anti-CD3z anti-
serum. As shown in Figure 3B, expression of CD3z was dramati-
cally decreased in effector CD4 T cells, whereas expression of the
CD3z-associated ZAP-70 kinase remained unchanged in lysates
from both fresh CD4 T cells and in vitro–generated effector T cells
(Figure 3B, upper blot). This dramatic loss of CD3z expression in
effector T-cell lysates ranged from 0% to less than 10% of the level
seen in resting T cells in 30 different experiments using puriﬁed T
cells obtained from 30 different donors. When taken together, the
results in Figure 3, panels A and B, demonstrate a profound and
speciﬁc loss of CD3z protein expression in effector CD4 T cells
concomitant with an increase in tyrosine phosphorylation of
speciﬁc proteins.
We asked whether this loss of CD3z protein expression
occurred at the transcriptional level, by assaying for the presence of
CD3z and ZAP-70 transcripts using RT-PCR. As shown in Figure
3C, both resting CD4 T cells and puriﬁed effector CD4 T cells
expressed comparable levels of CD3z transcripts, and likewise
expressed similar levels of ZAP-70 transcripts (lanes 1 and 2).
Monocytes, as expected, did not express either CD3z or ZAP-70
transcripts (Figure 3C, lane 3). These results demonstrate that the
loss of CD3z expression in effector CD4 T cells occurs after
transcription.
We also asked whether the loss of CD3z expression in effector
cell lysates was speciﬁc for the z chain of the CD3 complex or also
included other CD3 chains. To address this question we probed
lysates from resting and effector CD4 T cells with antiserum
directed against CD3z, CD3e, and as controls, ZAP-70 and actin.
As shown in Figure 3D, effector CD4 T cells exhibited dramatic
decreases in the expression of both CD3z and CD3e chains,
whereas ZAP-70 and actin expression remained constant. These
results indicate that expression of CD3z and CD3e are comodu-
lated in effector CD4 T cells.
Figure 3. Biochemical analysis of effector CD4 T cells reveals alterations in
tyrosine phosphorylation and loss of CD3z and CD3e protein expression.
Puriﬁed CD4 T cells from peripheral blood were used to generate effector cells using
OKT3 antibody and autologous monocytes (see “Materials and methods”). CD4 cells
and effectors were then left untreated (0) or cross-linked for 2 minutes with IgM
anti-CD3 antibody (CD3) before lysis. Lysates from 106 CD4 T cells (lanes 1 and 2),
and equivalent numbers of effector CD4 T cells (designated as ce, for cell
equivalents, lanes 3 and 4), or equivalent levels of total effector cell protein
(designated as pe, for 20mg protein equivalents, lanes 5 and 6) were resolved on
reducing 12.0% SDS-PAGE, blotted to nitrocellulose, and probed sequentially with
antiphosphotyrosine (A), followed by stripping and reprobing with anti-CD3z and
anti–ZAP-70 antisera (B). These blots are representative results from 19 individual
donors. In panel A, the effector-associated phosphorylated species of molecular
weights 120/121, 76, 72, 60, 40/41, 37, and 10 kd are indicated on the right side of the
blot. Bands of 135 kd and the phosphorylated CD3z band present in CD4 T-cell
lysates, but not in effector T cells are indicated on the left side of the blot. (C) RT-PCR
analysis of CD3z, ZAP-70, and actin transcript ampliﬁed from equal amounts of RNA
isolated from resting CD4 T cells (CD4), effector CD4 T cells (Eff), and monocytes
(mc). This gel is representative of 5 experiments. (D) Expression of ZAP-70, actin,
CD3e, and CD3z protein products in lysates of resting and effector CD4 T cells.
Protein equivalents (4 mg/lane) from lysates of CD4 T cells or 5-day activated effector
CD4 T cells puriﬁed as above were resolved by 4% to 20% gradient reducing
SDS-PAGE, blotted to nitrocellulose, and blots were cut into strips and hybridized
with polyclonal antiserum directed against ZAP-70, actin, CD3e, and CD3z.I B
indicates immunoblot.
Figure 2. Puriﬁcation of in vitro–generated effector cells results in removal of
residual monocytic accessory cells. (A) Extent of monocyte contamination in
effector CD4 T-cell preparations before monocyte depletion with anti-CD14 beads
and after depletion. (B) CD4 expression proﬁle of puriﬁed effector CD4 T cells.
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We asked whether this dramatic loss of CD3z and CD3e protein
expression was due exclusively to prolonged contact with anti-CD3
as the activating stimulus. We thus compared the expression of
CD3z, CD3e, and ZAP-70 and actin in fresh primary resting CD4T
cells before and after 72 hours of continuous culture in the presence
of anti-CD3 immobilized on plastic, immobilized anti-CD3 and
anti-CD28, or anti-CD3/monocytes (Figure 4). Although substan-
tial down-regulation of CD3z was observed in effector cells
generated with anti-CD3/monocytes to 8% of the level observed in
resting cells (Figure 4, lane 4), there was a gradation of CD3z loss
in anti-CD3 and anti-CD3/anti-CD28–stimulated T cells to 30%
and 13%, respectively, of the level seen in resting T cells (Figure 4,
compare lanes 2 and 3 to lane 1). CD3e expression, by contrast,
was reduced to similar extents for all stimulation conditions. All
cells exhibited comparable levels of ZAP-70 and actin protein
expression (Figure 4), and stimulation with soluble anti-CD3 alone
(data not shown) or monocytes alone (Figure 5A) did not affect
CD3z or CD3e expression.
Alterations in CD3z and TCR expression during
effector T-cell differentiation
Our ﬁndings of a reduction in expression of CD3z in effector CD4
T cells bore striking parallels to the loss of CD3z identiﬁed in
human T cells associated with chronic diseases such as SLE,24
cancer,25 and chronic viral infection.26 We reasoned that our system
provided a means to analyze the kinetics of CD3z down-regulation,
to determine how CD3z down-regulation affected surface TCR and
CD3e expression, and to make a direct comparison of CD3z
expression in naive, effector and memory CD4 T cells.
To analyze the kinetics of CD3z down-regulation during
effector T-cell differentiation, we cultured naive CD4 T cells with
anti-CD3 and monocytes for periods of time between 24 and 120
hours, and assessed the expression of CD3z (Figure 5).As shown in
Figure 5A, both CD3z and CD3e expression were substantially
reduced 24 hours after activation (lane 2) and remained low for 48
to 72 hours (lanes 3 and 4). There was some ﬂuctuation in CD3z
expression at 48 to 72 hours, which occurred in 3 of the 5 kinetic
experiments performed (Figure 5B). When 72-hour effector CD4 T
cells were removed from the activating stimulus and recultured in
media alone for 2 days, CD3z was re-expressed although at a lower
level than originally present in resting CD4 T cell lysates (Figure
5A, compare lane 5 to lane 1). As a control, CD4 T cells cultured
for 72 hours with monocytes maintained high levels of CD3z
expression (Figure 5A, lane 6), and all cells examined expressed
comparable levels of actin and ZAP-70 protein (Figure 5A, upper
blots). We compiled densitometric analysis of CD3z expression
Figure 4. Varying activation conditions results in differential loss of CD3z.
Resting CD4 T cells (lane 1) were cultured for 72 hours in the presence of
immobilized anti-CD3 (lane 2, anti-CD3), immobilized anti-CD3 and anti-CD28 (lane
3, CD31CD28), or with anti-CD3 and autologous monocytes (lane 4, CD31mc).
Cells were puriﬁed through Ficoll, and residual monocytes were depleted with
anti-CD14 coupled Dynabeads before lysis. Lysates containing equal protein levels
(4.1 mg/ lane) were resolved on a 4% to 20% gradient reducing SDS-PAGE and
blotted to nitrocellulose, cut into strips, and probed with anti–ZAP-70, antiactin,
anti-CD3e, and anti-CD3z antiserum. Lysates of puriﬁed monocytes (lane 5, mc) were
run as blotting controls. The relative expression of CD3z determined by dividing the
band densities in activated cells by the band density in resting CD4Tcells is indicated
at the bottom of each lane. This partial reduction of CD3z expression with CD3 and
CD3/CD28-stimulated T cells was observed in 5 different experiments.
Figure 5. Kinetics of CD3 and TCR down-regulation
during effector CD4 T cell differentiation. CD4 T cells
were cultured with anti-CD3/monocytes, harvested 24 to
120 hours, and either lysed for immunoblotting or stained
and analyzed by FACS. (A) Kinetics of differentiation-
induced CD3z and CD3e down-regulation. Anti–ZAP-70,
actin, CD3e, and CD3z immunoblot of lysates derived
from CD4 T cells before activation (lane 1), CD4 T cells
harvested and puriﬁed 24 to 72 hours after culture with
anti-CD3/monocytes (lanes 2-4, 24, 48, 72), 72 hours
puriﬁed effector CD4 T cells rested in media alone for 2
days (lane 5, 721rst), or puriﬁed CD4 T cells cultured
with monocytes alone for 72 hours (lane 6, T1mc).
Molecularweightmarkersareindicatedatleft.(B)Change
in CD3z expression over time of activation.Acompilation
of the densitometric analysis of 5 separate kinetic experi-
ments (Exp 1-5) performed as in panel A with puriﬁed T
cells and monocytes from 5 different donors. Relative
CD3z expression is deﬁned as in Figure 4. In Exp 5
(shown in panelA), the 120-hour time point was not done.
(C) TCR/CD3 and surface marker expression during
effector differentiation. Histograms show surface expres-
sion of ab TCR and CD3e compared to control staining.
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results are presented in Figure 5B. As seen in this graph, CD3z
expression is drastically reduced in all cases after 24 hours of
activation, is re-expressed in some cases at a low level at 48 hours,
and is uniformly re-expressed to levels 40% to 100% of resting
cells after effector cells are removed from the activating stimulus.
When taken together, the results from these kinetic experiments
indicate that loss of CD3z occurs early in effector CD4 T-cell
differentiation and persists while effectors remain in the presence
of the activating stimulus.
Because expression of CD3z is required for optimal surface
expression of the TCR,27 and TCR down-regulation has also been
established as an early feature of T-cell activation,28 we examined
whether loss of surface TCR correlated with loss of CD3z during
effector cell differentiation. As shown in Figure 5C (ﬁrst row),
surface TCR expression was dramatically reduced early in the
differentiation process (within 24 hours) and remained down-
regulated throughout the culture period with low level surface
expression between 48 and 72 hours. Consistent with loss of CD3e
expression in cell lysates, CD3e surface expression was also
reduced after 24 hours and partially restored at 48 to 72 hours
(Figure 5C, second row). No down-regulation of TCR/CD3
expression was observed when naive CD4 T cells were incubated
with monocytes alone (Figure 5C, column 7), and both TCR and
CD3e were re-expressed when 72-hour effector cells were washed
and recultured in media. These data demonstrate that loss of CD3z
occurs with the same kinetics as the reduction in TCR/CD3e
surface expression, and that both TCR and CD3 components are
re-expressed in “rested” effector T cells removed from the activat-
ing stimulus.
Comparison of naive, effector, and memory CD4 T-cell subsets
Because effector CD4 T cells bear phenotypic and functional
similarities to the memory subset, we asked whether the changes in
CD3z and tyrosine phosphorylation observed in effector T-cell
lysates could likewise be observed in memory CD4 T cells. To
addressthisquestion,wecomparedthepatternoftyrosinephosphor-
ylation and CD3z expression in cell equivalents of puriﬁed naive
(CD45RA) and memory (CD45RO) CD4 T cells compared to
effector CD4 T cells generated in vitro from these subsets by
activation with anti-CD3/monocytes.As shown in Figure 6A, when
comparing resting (lanes 1 versus 5), or CD3–cross-linked (lanes 2
and 6) naive and memory subsets, the qualitative pattern of tyrosine
phosphorylation is similar, although quantitatively, memory CD4T
cells exhibit a lower level of tyrosine phosphorylation as also
shown by others.29 Effector CD4 T cells derived either from naive
T cells (primary effectors) or memory T cells (memory effectors)
exhibited a high level of tyrosine phosphorylation of effector-
associated bands identiﬁed in Figure 3A (Figure 6A, lanes 3, 4, 7,
and 8). CD3z was expressed at high levels in both naive and
memory T cells, yet was virtually absent in lysates from primary or
memory effectors (Figure 6B). These data indicate that the
increased tyrosine phosphorylation and loss of CD3z expression
distinguishes activated effector T cells from memory T cells and
that effector T cells derived from either naive or memory precur-
sors exhibit similar biochemical proﬁles.
Discussion
Effector CD4 T cells are central to both cellular and humoral
immunity and predominate in many types of chronic diseases. In
this study, we have undertaken a biochemical analysis of differenti-
ated human effector CD4 T cells to determine whether alterations
in TCR-mediated signaling accompany differentiation to effector T
cells and distinguish effector and memory CD4 T-cell subsets. We
generated human effector CD4 T cells that bore activation and
differentiation markers such as CD25 and CD45RO and were
functionally differentiated in their ability to produce effector
cytokines. Biochemically, effector T cells exhibited distinct pat-
terns of tyrosine phosphorylation and extended down-regulation of
CD3z and CD3e protein expression concomitant with a reduction
of surface TCR/CD3 expression. These biochemical changes were
speciﬁc to the effector subset and did not occur in memory CD4 T
cells, suggesting that TCR-mediated signal transduction in effector
CD4 T cells is distinct from naive and memory subsets.
We generated primary human effector CD4 T cells by in vitro
activation of freshly isolated naive (CD45RA) or whole CD4 T
cells with anti-CD3 antibody and primary autologous monocytes.
We designate these cells effectors based on established criteria such
as increased cell size, increased expression of differentiation
markers, and the ability to secrete large amounts of effector
cytokines when restimulated. In vitro differentiation of human
naive T cells has been accomplished in other studies using
anti-CD3 and exogeneously added IL-2 in the absence of accessory
cells,20,30 and polarized human Th1 and Th2 lines have been
generated by activation of human PBMCs with mitogens and
Figure6.Bothprimaryandmemoryeffectorsexhibitsimilartyrosinephosphor-
ylation and loss of CD3z expression, whereas memory CD4 T cells are more
similar to the naive subset. Puriﬁed naive (CD45RA) and memory (CD45RO) CD4
T cells were isolated from PBMCs from an individual donor. Primary effector cells
were generated from the CD45RAsubset and memory effectors were generated from
the CD45RO subset by activation with OKT3 antibody and autologous monocytes for
3 days. T-cell subsets were left untreated (2) or cross-linked for 2 minutes with IgM
anti-CD3 antibody (1) before lysis. Lysates from 106 cell equivalents of naive (lanes 1
and 2), primary effector (lanes 3 and 4), memory (lanes 5 and 6), and memory effector
(lanes 7 and 8) CD4 T cells were resolved on 12.0% SDS-PAGE, blotted to
nitrocellulose, and probed sequentially with antiphosphotyrosine (A), followed by
stripping and reprobing with anti-CD3z antiserum (B). These blots are representative
results from 12 different donors. Eff-spec indicates effector-speciﬁc bands.
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lipopolysaccharide-activated dendritic cells in the presence of IL-2
and anticytokine antibodies.32 The in vitro generation of effector T
cells as described here occurs in nonpolarizing conditions in the
presence of untreated primary autologous accessory cells without
exogeneously added cytokines.
Our results reveal several interesting and novel features of
TCR-mediated signaling in differentiated effector CD4 T cells that
have implications for effector T-cell function and survival. First,
effector CD4 T cells exhibit a high level of tyrosine phosphoryla-
tion of TCR signaling intermediates consistent with their ability to
produce high levels of the effector cytokine IFN-g when restimu-
lated. Second, despite this biochemical hyperactivity, there is a
profound loss of TCR/CD3 expression at the surface and in cell
lysates while expression of CD3-associated kinase ZAP-70 re-
mains constant.Third, these changes inTCR/CD3 expression occur
during the course of effector T-cell differentiation and in effector T
cells generated from naive or memory precursors. Below we
discuss these ﬁndings in the context of other studies on TCR
signaling and TCR/CD3 down-regulation.
The effector CD4 T cells examined here exhibit a high level of
tyrosine phosphorylation, particularly proteins of 120/121 kd,
which correspond in size to p120cbl33 and Fyb/SLAP,34 37 to 41 kd,
which correspond in approximate size to p38 and erk mitogen-
activated protein kinases,10,35 and 72 to 80 kd, which may include
the p72syk tyrosine kinase36 or the linker/adaptor molecule SLP-
76.37 We have found effector-associated tyrosine phosphorylated
species of comparable size expressed by mouse effector CD4 T
cells generated either by antigen or anti-CD3 activation,15 strongly
suggesting that phosphorylation of these proteins is a general
featureofdifferentiatedeffectorTcells.Wearecurrentlyinvestigat-
ing the activation state of these effector-speciﬁc tyrosine phosphor-
ylated species to elucidate the precise signaling pathways operative
in effector T cells.
The second main TCR-coupled signaling alteration identiﬁed
here is a substantial reduction in the expression of TCR and CD3
signaling components both on the effector T-cell surface and in
detergent lysates. Loss of either surface TCR expression and CD3z
expression has been previously associated in a number of studies
with short-term activation (minutes to hours) of mouse and human
T-cell clones, lines, and primary T cells. In human T cells, TCR
stimulation for 1 to 2 hours resulted in loss of CD3z expression in
human T cell clones38,39 and loss of surface TCR and/or CD3
expression in human T-cell clones and primary human T cells.38,40
In mouse T cells, transient loss of CD3z expression was demon-
strated in lysates of mouse primary T cells activated with anti-
CD3e for several hours41 and surface TCR expression was down-
modulated in primary mouse T cells 1 to 12 hours after stimulation
with anti-CD3e antibody41 or antigen/APC.42 Recently, surface
TCR and CD3e were found to be down-modulated in primary
mouse T cells activated with antigen/APC for 10 to 60 minutes, yet
the total amount of CD3z protein in cell lysates was unchanged
from the level in resting T cells.43 When taken together, these
published studies demonstrate a more pronounced activation-
induced decrease in CD3z expression in humanTcells compared to
mouse T cells. In our results, we found that expression of CD3z
was dramatically reduced during the course of human effector CD4
T-cell differentiation up to 5 days. By contrast, mouse effector CD4
T cells maintain expression of CD3z protein (data not shown),
suggesting that modulation of CD3z expression may be a unique
feature of human effector T cells.
We found that the extent of CD3z loss could be modulated by
changing the activation condition. We observed a greater loss of
CD3z expression when anti-CD3 stimulation was augmented by
cocross-linking CD28 or adding monocytic APC, suggesting that
the extent of CD3z down-regulation may be regulated by signal
strength as shown in studies of TCR down-regulation in T-cell
clones treated with peptide agonists and antagonists.44 Because it is
difﬁcult to isolate antigen-speciﬁc effector T cells without deﬁned
major histocompatibility complex (MHC) class II-tetramer re-
agents, we are currently examining whether CD3z loss occurs in
human effector CD4 T cells generated by alloantigen stimulation.
There are at least 3 possibilities to account for the apparent loss
of CD3z expression in effector T cells; ﬁrst, CD3z may partition to
another portion of the cell; second, CD3z may be degraded, and
ﬁnally, CD3z may be continuously and rapidly recycled through
the endocytic compartment. For the ﬁrst possibility, it has been
shown that as much as 40% of total cellular CD3z can associate to
the actin cytoskeleton in resting T cells and partitions to the
triton-insoluble pellet,45,46 suggesting that loss of CD3z expression
in NP40 lysates of effector T cells may be due to partitioning to the
cytoskeletal fraction. We think this possibility unlikely, however,
because we did not detect CD3z protein expression in the
NP40-insoluble pellet of effectorTcells, but did detect CD3z in the
insoluble fraction of resting CD4 T cells (data not shown). For the
latter 2 possibilities, it has been demonstrated in T-cell clones that
CD3z is lost due to proteolytic degradation,38 and TCR internaliza-
tion mediated through 2 different pathways—either through CD3g/
PKC or p56lck/p59fyn—has been demonstrated in the human Jurkat
T-cell line.47,48 Whether these processes occur in effector CD4 T
cells is currently being investigated.
Although the dramatic loss of CD3z expression also led to the
coordinate reduction in TCR/CD3 expression, the intracellular
CD3z-associated kinase, ZAP-70, was expressed at comparable
levels in resting and effector CD4 T cells. These ﬁndings contrast a
previous study that demonstrated a loss of ZAP-70 expression with
the same kinetics as CD3z down-regulation in a human T cell
clone.39 We are currently examining whether the ZAP-70 kinase is
active in human effector T cells, or whether another ZAP-70-
related kinase such as p72syk may function in place of ZAP-70 when
CD3z and CD3e expression is decreased.
When taken together, the signaling alterations identiﬁed here in
human effector T cells appear paradoxical. Whereas an increase in
tyrosine phosphorylation and IFN-g production suggests an aug-
mentation of intracellular signals consistent with potent effector
cell functions and increased activation kinetics,8 down-regulation
of TCR and CD3z suggests a diminution of TCR-mediated
proximal signaling. Signal extinction due to TCR down-regulation
has been demonstrated in T-cell clones in which TCR/CD3
down-regulation occurred.49 We propose that signaling in effector
CD4 T cells may occur in the absence of CD3z expression, either
through another TCR-signaling molecule or via activated kinases
such as ZAP-70. Alternately, the low level of CD3z re-expression
observed during effector T-cell differentiation (Figure 5A-B)
coupled with the enhanced phosphorylation may enable propaga-
tion of signals in effector T cells. Because effector T cells are
susceptible to apoptosis triggered by prolonged TCR occupancy,8
TCR/CD3z down-regulation may also serve to protect differentiat-
ing effector T cells from apoptosis. It was found that CD3z-
deﬁcient mouse primary T cells, or Jurkat cells, exhibited de-
creased susceptibility to activation-induced cell death but were not
impaired in activation parameters such as up-regulation of activa-
tion markers.50,51 Maintaining or increasing intracellular proximal
signals while down-regulating surface TCR and CD3z expression
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presence of prolonged TCR triggering that would otherwise have
led to apoptosis.
Our ﬁndings that effector CD4 T cells derived from naive or
memory precursors exhibit similar changes in tyrosine phosphory-
lation and CD3z expression suggest that examination of signaling
parameters in ex vivo human T cells may serve to reliably assess
their activation or differentiation state. In support of this idea,
signiﬁcant correlation can be drawn between our ﬁndings and
biochemical analyses of ex vivo–derived T cells from certain
disease states. For example, both an increase in total tyrosine
phosphorylation and loss of CD3z has been found in human T cells
isolated from patients with SLE.24 Moreover, T cells exhibiting a
reduction of CD3z expression have also been found in ex vivo
isolated tumor-inﬁltrating lymphocytes from human renal carci-
noma,52 synovial ﬂuid T cells in rheumatoid arthritis,53 and
peripheral T cells from individuals with active human immunodeﬁ-
ciency virus infection54 and Epstein-Barr virus and cytomegalovi-
rus infection.26 In light of our ﬁndings, it would be interesting to
examine the possibility that these disease-associated cells may
represent effector T cells generated as a result of chronic immune
activation. Indeed, the CD3z2 fraction of CD8 T cells associated
with chronic viral infections was found to express an activated/
effector phenotype and could likewise be stimulated to produce
IFN-g.26 Our ﬁndings that CD3z is re-expressed in effector T
cells following removal of the activating stimulus are also
consistent with the ability of CD3z2 T cells from chronic viral
infection to re-express CD3z when cultured in vitro26 or
following antiviral therapy.55
In summary, the alterations in overall TCR-mediated signaling
and TCR/CD3 expression in effector CD4 T cells suggest mecha-
nisms for the control of effector T-cell function and survival, and
can likewise be used to identify this subset in vivo.
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